This collaboration enhances Aspira's credibility in women's health AI diagnostics but provides no near-term revenue or product launch catalyst. Watch for future SOWs that may include funded milestones or license options. The stock may see a modest positive reaction from the partnership validation, but fundamentals remain unchanged.
Price Chart
Executive Summary
Aspira Women's Health entered a Master Collaboration and License Agreement with Cleveland Clinic to jointly develop AI-powered diagnostics for women's health. The five-year agreement includes a $125,000 non-refundable partnering fee but no specific funding for research projects, which will be defined under later Statements of Work. This is a strategic validation of Aspira's platform but lacks near-term revenue impact.
Key Facts
- Aspira pays CCF a $125,000 institutional partnering fee ($50,000 upfront, $25,000 annually for three years).
- Five-year initial term with mutual extension option; either party can terminate on 60 days' notice.
- Agreement covers biomarker discovery, AI modeling, and clinical validation for women's health diagnostics.
- No specific funded research projects or milestones were disclosed; future work requires separate Statements of Work.
- Collaboration is non-exclusive and does not grant Aspira any ownership of CCF background IP or data.
Financial Impact
Modest initial cash outflow of $50,000 within 30 days, plus $25,000 per year for three years; no revenue or earnings impact disclosed.
Risk Factors
- No guaranteed research milestones; collaboration may not yield commercial products.
- Aspira's limited cash resources may require future equity or debt financing to support R&D.
- Cleveland Clinic retains ownership of its background IP; any commercial license would require separate negotiation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000926617-26-000037 |
| Document: awhl-20260520x8k.htm | 0000926617-26-000037 |
| Document: awhl-20260520xex99d1.htm | 0000926617-26-000037 |
| Document: 0000926617-26-000037-index-headers.html | 0000926617-26-000037 |
| Document: 0000926617-26-000037-index.html | 0000926617-26-000037 |
| Document: 0000926617-26-000037.txt | 0000926617-26-000037 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 22, 2026 18w ago | 8-K | $0.4600 $0.2900 | ▲ +36.96% | ▲ +39.17% | $0.1387 (+69.85%) |
Jun 9, 2026 20w ago | 8-K | $0.4300 $0.2786 | ▲ +35.21% | ▲ +39.29% | $0.1387 (+67.74%) |
May 29, 2026 21w ago | Insider Cluster | $0.5400 $0.2700 | ▼ −50.00% | ▼ −51.23% | $0.1387 (−74.31%) |
May 26, 2026 22w ago | 8-K | $0.4600 $0.3100 | ▼ −32.61% | ▼ −35.33% | $0.1387 (−69.85%) |
Apr 30, 2026 25w ago | 8-K | $0.3900 $0.3509 | ▼ −10.03% | ▼ −13.09% | $0.1387 (−64.44%) |
Apr 28, 2026 25w ago | DEFA14A | $0.4000 $0.4000 | · 0.00% | ▼ −4.11% | $0.1387 (−65.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers